Compare DexCom, Inc. (DXCM) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Standard Lithium Ltd — how do they compare? DexCom, Inc. trades at $83.83 (market cap $31.86B), while Standard Lithium Ltd trades at $1.63 (market cap $398.07M). The key difference: DexCom, Inc. is far larger — about 80× Standard Lithium Ltd's market cap, and DexCom, Inc. is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| DXCM | SLI | |
|---|---|---|
Market Cap | $31.86B | $398.07M |
Volume | 3,607,070 | 1,564,155 |
Sector | Health | Basic Materials |
52-Week High | $92.34 | $5.65 |
52-Week Low | $54.84 | $1.61 |
Enterprise Value | $31.32B | $260.98M |
Typical Hold Time | — | 23 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Standard Lithium (SLI) trades at $1.615, down 2.12% today, with a bearish technical signal despite oversold RSI readings. The company shows negative profitability with ROE at -15.55% and no revenue in 2025, but has achieved key project milestones including customer offtake agreements with LG Energy Solution and Trafigura. Analyst consensus remains strongly bullish with a $3.83 price target, reflecting optimism about the Arkansas lithium project's 2026 final investment decision.
The investment case hinges on successful execution of the South West Arkansas lithium project, which could transform SLI from development to production phase. Key risks include project delays, funding requirements, and lithium price volatility. With 100% analyst buy ratings and institutional backing from BlackRock and Amundi, the stock offers high-risk, high-reward potential for investors betting on North American lithium production growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
